Pirfenidone (Esbriet) has finally been added to the PBS for patients with idiopathic pulmonary fibrosis (IPF). The PBS subsidy will come as a relief for patients who have been waiting for a number of years for improved access to the drug. The Pharmaceutical Benefits Advisory Committee (PBAC) has previously recognised ‘the high clinical need for ...
Already a member?
Enter your email to keep reading.